PAIN SYNDROMES IN MULTIPLE SCLEROSIS PATIENTS
|
|
|
- Melinda Cory Ward
- 9 years ago
- Views:
Transcription
1 Acta Clin Croat 2014; 53: Original Scientific Paper PAIN SYNDROMES IN MULTIPLE SCLEROSIS PATIENTS PATIENT EXPERIENCE AT Lipik Special hospital for medical rehabilitation Viktor Vidović 1, Merisanda Časar Rovazdi 1, Senka Rendulić Slivar 1, Oto Kraml 1 and Vanja Bašić Kes 2 1 Lipik Special Hospital for Medical Rehabilitation, Lipik; 2 Clinical Department of Neurology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia SUMMARY In the study, we evaluated 61 multiple sclerosis patients hospitalized at our hospital in the period from October 1, 2013 to February 15, The aim of the study was to investigate pain syndromes associated with the underlying disease. Pain in the month preceding assessment was reported by 90% of patients. Most patients suffered from low back pain (52%) and musculoskeletal pain (39%), followed by neck pain (31%), painful tonic spasm (26%), neuropathic extremity pain (23%) and pain due to spasticity (21%). Other types of pain were present in less than 20% of patients. A total of 67% of patients were taking analgesics; the most frequently used were nonsteroidal antiinflammatory drugs, while drugs against neuropathic pain were taken by a smaller number of patients. The high incidence of pain syndromes pointed to the importance of regular physical therapy procedures. Key words: Multiple sclerosis; Pain; Analgesics Introduction Pain is an unpleasant sensory and emotional experience associated with existing or impending tissue damage (International Association for the Study of Pain, 2012 revised definition). Based on the pathogenesis, pain can be nociceptive, neuropathic or psychosomatic. Nociceptive pain occurs due to existing or impending damage to non-neural tissue and results from the activation of nociceptors sensory pain receptors in the peripheral somatosensory nervous system. It is classified as somatic or visceral pain. Somatic pain occurs through the activation of nociceptors located in somatic structures (skin, subcutaneous tissue, muscles and joints). Visceral pain is initiated through the activation of nociceptors located in visceral structures (internal organs). Correspondence to: Viktor Vidović, MD, Lipik Special Hospital for Medical Rehabilitation, Lipik, Marije Terezije 13, HR Lipik, Croatia viktor.vidovic@ bolnica-lipik.hr Received July 8, 2014, accepted September 11, 2014 Neuropathic pain is caused by damage to or disease of the somatosensory nervous system. It is classified as either central or peripheral. Central neuropathic pain is caused by damage to or disease of the central somatosensory nervous system (spinal cord, brainstem, thalamus and its projections towards the cerebral cortex). Peripheral neuropathic pain is caused by damage to or disease of the peripheral somatosensory nervous system. It occurs in conditions that affect individual or multiple nerves (neuralgia of the nerves, polyneuropathy, radiculopathy). Previous studies have often ignored pain as an important symptom in patients with multiple sclerosis (MS) 1. The estimated prevalence of pain in patients with MS varies in different studies from 26% to 86% The reason behind this is the existence of large differences in the patient sample surveyed, use of different research methods, testing different pain localizations and use of different criteria for defining a particular pain syndrome associated with MS 9. There is no internationally recognized classification of pain Acta Clin Croat, Vol. 53, No. 4,
2 syndromes in MS patients. This study involved the use of a modified classification as proposed by Truini et al. 12. The mentioned authors classify pain in those suffering from MS as neuropathic pain (neuropathic pain in the limbs, trigeminal neuralgia, Lhermitte s sign), mixed pain (painful tonic spasms, pain due to spasticity), nociceptive pain (pain due to optic neuritis, musculoskeletal and joint pain, back pain, migraine, tension headache, pain due to therapy) and other pain syndromes. Patients and Methods This study analyzed the presence, incidence, localization, type and strongest intensity of pain in patients with MS over a period of one month prior to hospitalization in our institution. In addition, the frequency and types of analgesics used in the mentioned period were analyzed. Respondents were people with MS who underwent inpatient rehabilitation in the Lipik Special Hospital for Medical Rehabilitation in the period between October 1, 2013 and February 15, The study included patients older than 18 years with a diagnosis of MS according to the revised Mc- Donald criteria 13. The exclusion criterion was serious cognitive damage. Based on the exclusion criterion, three patients were not enrolled in the study. Information was collected on each patient regarding their age, gender, type of MS, time elapsed since being diagnosed, presence of pain, pain severity, analgesic and spasmolytic therapy. In each patient, the level of incapacity was determined based on the Expanded Disability Status Scale (EDSS) score 14. The severity of pain was measured using a visual analog scale (VAS), whereas cognitive status assessment was performed using the Mini Mental Status 15. The study was approved by the Hospital Ethics Committee, and a written consent for participation was obtained from study patients. Results The study included 61 subjects, 44 (72%) women and 17 (28%) men, mean age 47.5 (range, 27-71). The mean time elapsed since being diagnosed with MS 36% 7% Fig. 1. Types of multiple sclerosis. 57% RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; PPMS = primary progressive MS was 10.9 years (range, 6 months to 38 years). Of the total number of patients, 35 (57%) patients had the relapsing-remitting form of the disease (RRMS), 22 (36%) secondary progressive form (SPMS), and four (7%) primary progressive form (PPMS) (Fig. 1). The mean EDSS was 5.5 (range, 1.5-9). Fifty-five (90%) patients reported experiencing pain for one month prior to hospitalization, 44 (72%) of them having experienced pain in more than one location. Most patients had back pain, followed by musculoskeletal and joint pain, neck pain, painful tonic spasms, neuropathic pain and pain in the extremities caused by spasticity. Less than 20% experienced the following in the respective order: migraine headaches, group of other types of pain, tension headaches and Lhermitte s phenomenon, pain due to therapy, and neuralgia of the trigeminal nerve. Table 1. Incidence of particular pain syndromes RRMS SPMS PPMS Pain syndrome n % Neuropathic extremity pain Trigeminal neuralgia 2 3 Lhermitte's sign 5 8 Painful tonic spasm Spasticity pain Optic neuritis pain 0 0 Muscle, joint and skeletal pain Low back pain Migraine Tension-type headache 5 8 Treatment-induced pain 4 7 Other pain 7 11 Neck pain Acta Clin Croat, Vol. 53, No. 4, 2014
3 Neck pain Other pain Treatment induced pain Tension-type headache Migraine Low back pain Muscle, joint and skeletal pain Optic neuritis pain Spasticity pain Painful tonic spasm Lhermitte s sign Trigeminal neuralgia Neuropathic extremity pain Fig. 2. Mean pain intensity according to localization (visual analog scale). None of the patients had optic neuritis during that period. There were two patients in the group experiencing other types of pain who complained of pain in the abdomen, followed by two who had pain in their eyes and one patient with post-herpetic neuralgia, pain in the chest and due to decubitus ulcer. Pain as a side effect of therapy was reported by four subjects; two had myalgia as a result of taking interferon, and another two pain due to needle injections when taking glatiramer acetate (Table 1). Analysis of average pain intensity of each pain syndrome measured according to VAS revealed that patients reported tonic spasms as the most painful syndrome, followed by migraine headaches, then back pain and neuropathic pain in the extremities (Fig. 2). Forty-one (67%) patients were taking analgesics, 18% of them on daily basis (Fig. 3). Analysis of the types of analgesics showed that 58% of patients were taking nonsteroidal antirheu- 33% 16% 18% 26% 7% Every day 4-6 times per week 1-3 times per week Less than once per week Table 2. Drug used for neuropathic pain relief Drug n % Antiepileptic 3 23 Antidepressant 0 0 Tramadol 8 62 Combination 2 15 matic drug as monotherapy, 15% a drug to reduce neuropathic pain as monotherapy, 10% other analgesics (paracetamol alone or in combination with analgesics), and a combination of non-steroidal antirheumatic drugs and medication to reduce neuropathic pain amounting to 17% (Fig. 4). 10% 15% 17% 58% Non-steroidal antirheumatic Drug for reducing neuropathic pain Other analgesics Combination Never Fig. 3. Frequency of medication (%). Fig. 4. Types of analgesics. Acta Clin Croat, Vol. 53, No. 4,
4 Among drugs taken for neuropathic pain relief, tramadol was most common, followed by antiepileptic, and then a combination of tramadol and antiepileptic drugs (Table 2). Spasmolytics were taken by 27 (45%) patients, of which 15 (56%) took baclofen, 9 (33%) diazepam, and three (11%) took a combination of these two drugs. Discussion The study showed the presence of pain in 90% of patients with MS. Due to differences in patient sample, use of different research methods, testing of different localizations of pain and use of different criteria to define a particular pain syndrome associated with MS, only a partial comparison with other studies is possible. Studies that conducted meta-analyses have shown the incidence of pain in 75% of patients over a period of one month prior to testing 9. In a meta-analysis conducted by Foley et al., the studies included different periods when testing pain and the incidence of pain was 63% 7. In a study by Archibald et al., which included 85 patients, the incidence of pain for a period of one month prior to testing was 53% 16, while the study by Bacher Svendsen et al., which included 771 patients, showed that pain was more frequent in 79.4% of the respondents 2. Our study showed a slightly higher incidence of pain syndromes compared to these studies. This may be because our patients were referred to inpatient rehabilitation, thereby excluding those with minor functional deficits that are rarely treated as inpatients. Most of our patients had back pain (52%), musculoskeletal and joint pain (39%), neck pain (31%), painful tonic spasms (26%), neuropathic pain in the extremities (23%), pain due to spasticity (21%) and migraine headaches (16%). Compared to a meta-analysis that included 17 studies 7, comparable incidence of neuropathic pain in the extremities and trigeminal neuralgia was recorded in our study; however, we found less headaches (migraines and tension headaches), while there was a higher incidence of back pain and painful tonic spasms. The highest incidence of back pain including musculoskeletal and joint pain could be explained by the fact that these pains are common in the general population 17-19, while Truini et al. conclude that postural abnormalities caused by neurologic deficits contribute to an increase in the prevalence of the listed pain syndromes 12. Analyzing the intensity of pain in a particular pain syndrome, it becomes evident that the most painful experience are tonic spasms, followed by migraine headaches, then back pain and neuropathic pain in the extremities. A total of 67% of respondents were taking analgesics, 90% of them experiencing pain. Another 11% of patients experiencing pain were taking only spasmolytics (as monotherapy). This means that some patients were avoiding taking analgesics (stating concern about the drug side effects), while some were mitigating the effects of pain by using spasmolytics as monotherapy. Nonsteroidal antirheumatic drugs were the most often administered analgesics. Drugs for reducing neuropathic pain, predominantly tramadol, were taken by a small number of patients, followed by antiepileptic drugs. None of the study patients was taking antidepressants, which are otherwise also recommended for the treatment of pain 20. Fourteen patients were taking medication for reducing neuropathic pain, alone or in combination with nonsteroidal antirheumatic drugs. In the total sample, 20 patients had pain classified as neuropathic in the narrow sense (neuropathic pain in the extremities, Lhermitte s sign, trigeminal neuralgia). Of these 20 patients, seven were taking medication for reducing neuropathic pain, while another seven were taking tramadol for back pain, neck and muscle-joint-bone pain. When taking into account that chronic back pain was also partly experienced as a neuropathic component, hypo-utilization of the listed drug groups is also a possibility, but only a small number of patients may have had an impact on the result. Conclusions Pain is a common problem in people with MS. In this study, pain was present in 90% of patients over a period of one month prior to hospitalization. The most common form of pain was back pain including musculoskeletal and joint pain, partly due to the high prevalence of pain syndromes listed in the general population. Postural abnormalities caused by neurologic deficits are an additional cause of these pain 408 Acta Clin Croat, Vol. 53, No. 4, 2014
5 syndromes. Approximately 20%-25% of respondents stated that they were affected by neuropathic pain in the extremities, painful tonic spasms and pain caused by spasticity. The above syndromes in the sample of patients may be associated with MS. A total of 67% of the respondents were taking analgesics and 25% were taking drugs four days a week or more frequently. The most common were nonsteroidal antirheumatic drugs, while drugs for reducing neuropathic pain were taken only by a small number of patients. Given the prevalence of pain syndromes and frequent use of analgesics, it becomes evident that regular physical therapy procedures are important; besides being aimed at reducing functional deficit or maintaining an existing one, they significantly influence reduction of pain components. References 1. TOURTELLOTE WW, BAUMHEFNER WW. Comprehensive management of multiple sclerosis. In: Hallpike FJ, Adams CWM, Tourtellote, WW, editors. Multiple sclerosis. Philadelphia: Lippincott Williams & Wilkins, 1983: BACHER SVENDSEN K, JENSEN TS, OVERVAD K, HANSEN HJ, KOCH-HENRIKSEN N, BACH FW. Pain in patients with multiple sclerosis. A population-based study. Arch Neurol 2003;60: BAŠIĆ-KES V, IVANKOVIĆ M, BITUNJAC M, GOV- ORI B, ZAVOREO I, DEMARIN V. Pain in multiple sclerosis. Med Sci 2009;33: BONESCHI FM, COLOMBO B, ANNOVAZZI P, MAR- TINELLI V, BERNASCONI L, SOLARO C, COMI G. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler 2008;14: CLIFFORD DB, TROTTER JL. Pain in multiple sclerosis. Arch Neurol 1984;41: EHDE DM, OSBORNE TL, HANLEY MA, JENSEN MP, KRAFT GH. The scope and nature of pain in persons with multiple sclerosis. Mult Scler 2006;12: FOLEY PL, VESTERINEN HM, LAIRD BJ, SENA ES, COLVIN LA, CHANDRAN S, MACLEOD MR, FALLON MT. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and metaanalysis. 2013;154: NURMIKKO TJ, GUPTA S, MACLVER K. Multiple sclerosis-related central pain disorder. Curr Pain Headache Rep 2010;14: O CONNOR AB, SCHWID SR, HERRMANN DN, MARKMAN JD, DWORKIN RH. Pain associated with multiple sclerosis: systematic review and proposed classification. 2008;137: PIWKO C, DESJARDINS OB, BEREZA BG, MACHA- DO M, JASZEWSKI B, FREEDMAN MS, EINARSON TR, ISKEDJIAN M. Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada. Pain Res Manag 2007;12: STENAGER E, KNUDSEN L, JENSEN K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991;84: TRUINI A, BARBANTI P, POZZILLI C, CRUCCU G. A mechanism-based classification of pain in multiple sclerosis. J Neurol 2013;260: POLMAN CH, REINGOLD SC, EDAN G, FILIPPI M, HARTUNG HP, KAPPOS L, LUBLIN FD, METZ LM, McFARLAND HF, O CONNOR PW, SANDBERG- WOLLHEIM M, THOMPSON AJ, WEINSHENKER BG, WOLINSKY JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005;58: KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. Minimental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: ARCHIBALD CJ, McGRATH PJ, RITVO PG, FISK JD, BHAN V, MAXNER CE, MURRAY TJ. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994;58: BALAQÉ F, MANNION AF, PELLISÉ F, CEDRASCHI C. Non-specific low back pain. Lancet 2012;379(9814): BENER A, VARJEE M, DAFEEAH EE, FALAH O, Al-JUHAISHI T, SCHLOGL J, SEDEEQ A, KHAN S. Psychological factors: anxiety, depression, and somatisation symptoms in low back pain patients. J Pain Res 2013;6: CIMMINO MA, FERRONE C, CUTOLO M. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 2011;25: BAŠIĆ-KES V, ZAVOREO I, ŠERIĆ V, VARGEK SOLT- ER V, CESARIK M, HAJNŠEK S, BOŠNJAK PAŠIĆ M, GABELIĆ T, BAŠIĆ S, SOLDO BUTKOVIĆ S, LUŠIĆ I, DEŽMALJ GRBELJA L, VLADIĆ A, BIELEN I, ANTOČIĆ I, DEMARIN V. Recommendations for diagnosis and management of multiple sclerosis. Acta Clin Croat 2012;51: Acta Clin Croat, Vol. 53, No. 4,
6 Sažetak BOLNI SINDROMI U OBOLJELIH OD MULTIPLE SKLEROZE ISKUSTVA BOLESNIKA LIJEČENIH U SPECIJALNOJ BOLNICI ZA MEDICINSKU REHABILITACIJU U LIPIKU V. Vidović, M. Časar Rovazdi, S. Rendulić Slivar, O. Kraml i V. Bašić Kes U studiji je obuhvaćen 61 oboljeli od multiple skleroze. Svi su bili hospitalizirani u našoj ustanovi od 1. listopada do 15. veljače Cilj rada je bio istražiti bolne sindrome pridružene osnovnoj bolesti. Bolovi su bili prisutni u 90% ispitanika. Najveći broj oboljelih imao je bolove u leđima (52%) i mišićno-zglobno-koštane bolove (39%), nakon čega slijede bolovi u vratu (31%), bolni tonički spazmi (26%), neuropatski bolovi u ekstremitetima (23%) i bolovi uslijed spasticiteta (21%). Drugi tipovi bolova bili su prisutni u manje od 20% oboljelih. Analgetike je uzimalo 67% ispitanika, najčešće nesteroidne antireumatike, dok je lijekove protiv neuropatskih bolova uzimao manji broj bolesnika. Visoka učestalost bolnih sindroma ukazuje na važnost redovitih postupaka fizikalnih terapija. Ključne riječi: Multipla skleroza; Bol; Analgetici 410 Acta Clin Croat, Vol. 53, No. 4, 2014
06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
Natural Modality in the Treatment of Primary Headaches. William S. Mihin, D.C. Catharine Helms, M.S. Michelle M. Anderson, M.S.N., F.N.P.
Natural Modality in the Treatment of Primary Headaches William S. Mihin, D.C. Catharine Helms, M.S. Michelle M. Anderson, M.S.N., F.N.P. Abstract Headaches are both a prevalent and disabling condition.
Mellen Center Approaches: Pain in Multiple Sclerosis
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Pain in Multiple Sclerosis How often do MS patients have pain? The point prevalence of
Clinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
Mellen Center Approaches: Pain in Multiple Sclerosis
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Pain in Multiple Sclerosis Q: How often do MS patients have pain? A: Pooled overall pain
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
Relapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
New perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
How To Use A Drug In Multiple Sclerosis
Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and
Accuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.
Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.
Clinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
PAIN IN MULTIPLE SCLEROSIS PATIENTS BOL KOD OBOLJELIH OD MULTIPLE SKLEROZE
ORIGINAL ARTICLE UDC: 616.83-4-9.7 PAIN IN MULTIPLE SCLEROSIS PATIENTS BOL KOD OBOLJELIH OD MULTIPLE SKLEROZE Sanja Grgić 1, Aleksandra Dominović- Kovačević 1, Zoran Vukojević 1, Duško Račić 1 Abstract:
Multiple sclerosis information
Multiple sclerosis information for health and social care professionals MS: an overview Diagnosis Types of MS Prognosis Clinical measures A multidisciplinary approach to MS care Self-management Relapse
Webinar title: Know Your Options for Treating Severe Spasticity
Webinar title: Know Your Options for Treating Severe Spasticity Presented by: Dr. Gerald Bilsky, Physiatrist Medical Director of Outpatient Services and Associate Medical Director of Acquired Brain Injury
Using the MS Clinical Course Descriptions in Clinical Practice
Using the MS Clinical Course Descriptions in Clinical Practice Mark J. Tullman, MD Director of Clinical Research The MS Center for Innovations in Care Missouri Baptist Medical Center Disclosures Consultant/speaking
Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
Tension Type Headaches
Tension Type Headaches Research Review by : Dr. Ian MacIntyre Physiotherapy for tension-type Headache: A Controlled Study P. Torelli, R. Jenson, J. Olsen: Cephalalgia, 2004, 24, 29-36 Tension-type headache
CHPN Review Course Pain Management Part 1 Hospice and Palliative Nurses Association
CHPN Review Course Pain Management Part 1 Disclosures Bonnie Morgan has no real or perceived conflicts of interest that relate to this presentation. Copyright 2015 by the. HPNA has the exclusive rights
Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis
PAIN Ò 154 (2013) 632 642 www.elsevier.com/locate/pain Comprehensive review Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis Peter L. Foley
Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
Managing Pain. For People Living with MS
Managing Pain For People Living with MS FreecallTM 1800 042 138 www.msaustralia.org.au Managing Pain For People Living with MS Published by: Multiple Sclerosis Limited ABN: 66 004 942 287 MS Australia
Natalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
Effects of Acupuncture on Chronic Lower Back Pain. Audience: Upper Division IPHY Majors
1 Effects of Acupuncture on Chronic Lower Back Pain Audience: Upper Division IPHY Majors Introduction: Lower back pain is the leading cause of limited physical activity and the second most frequent reason
OHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines
TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central
MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION
MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION Michael K. Racke, MD Professor and Chairman in Neurology The Helen C. Kurtz Chair in Neurology Department of Neurology Ohio State University
LOW BACK PAIN; MECHANICAL
1 ORTHO 16 LOW BACK PAIN; MECHANICAL Background This case definition was developed by the Armed Forces Health Surveillance Center (AFHSC) for the purpose of epidemiological surveillance of a condition
Which injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
1st Edition 2015. Quick reference guide for the management of acute whiplash. associated disorders
1 1st Edition 2015 Quick reference guide for the management of acute whiplash associated disorders 2 Quick reference guide for the management of acute whiplash associated disorders, 2015. This quick reference
Chronic pain in multiple sclerosis: An overview
American Journal of Internal Medicine 2014; 2(2): 20-25 Published online March 20, 2014 (http://www.sciencepublishinggroup.com/j/ajim) doi: 10.11648/j.ajim.20140202.13 Chronic pain in multiple sclerosis:
Pain is a common symptom reported
MULTIPLE SCLEROSIS FACT SHEET MANAGING YOUR PAIN Pain is a common symptom reported by people with multiple sclerosis (MS). Approximately 50-60% of people with MS experience acute or chronic pain at some
Clinical and Therapeutic Cannabis Information. Written by Cannabis Training University (CTU) All rights reserved
Clinical and Therapeutic Cannabis Information Written by Cannabis Training University (CTU) All rights reserved Contents Introduction... 3 Chronic Pain... 6 Neuropathic Pain... 8 Movement Disorders...
Tension-type headache Non-pharmacological and pharmacological treatment
Danish Headache Center Tension-type headache Non-pharmacological and pharmacological treatment Lars Bendtsen Associate professor, MD, PhD, Dr Med Sci Danish Headache Center, Department of Neurology Glostrup
Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València
Rational basis for early treatment in MS Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València Bonaventura Casanova Department of Neurology University Hospital La
A Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
Natural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d
Natural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d Purpose of review To highlight progress in the description of the natural
PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004
Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective
Muscular Dystrophy and Multiple Sclerosis. ultimately lead to the crippling of the muscular system, there are many differences between these
Battles 1 Becky Battles Instructor s Name English 1013 21 November 2006 Muscular Dystrophy and Multiple Sclerosis Although muscular dystrophy and multiple sclerosis are both progressive diseases that ultimately
International Journal of Economics, Commerce and Management United Kingdom Vol. II, Issue 2, 2014
International Journal of Economics, Commerce and Management United Kingdom Vol. II, Issue 2, 2014 http://ijecm.co.uk/ ISSN 2348 0386 HEALTHCARE MANAGEMENT AND PSYCHOLOGICAL WELL-BEING IN PATIENTS WITH
HEADACHE. as. MUDr. Rudolf Černý, CSc. doc. MUDr. Petr Marusič, Ph.D.
HEADACHE as. MUDr. Rudolf Černý, CSc. doc. MUDr. Petr Marusič, Ph.D. Dpt. of Neurology Charles University in Prague, 2nd Faculty of Medicine Motol University Hospital History of headache 1200 years B.C.
Autoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system
6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S.
High Prevalence and Incidence Prevalence 85% of Americans will experience low back pain at some time in their life. Incidence 5% annual Timothy C. Shen, M.D. Physical Medicine and Rehabilitation Sub-specialty
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
Careful Coding: Headaches
Dynamic Chiropractic March 26, 2012, Vol. 30, Issue 07 Careful Coding: Headaches By K. Jeffrey Miller, DC, DABCO and Ray Tuck, DC Because s are among the most common reasons for seeking chiropractic care,
Making our pets comfortable. A modern approach to pain and analgesia.
Making our pets comfortable. A modern approach to pain and analgesia. What is pain? Pain is an unpleasant sensory and emotional experience with awareness by an animal to damage or potential damage to its
Sample Treatment Protocol
Sample Treatment Protocol 1 Adults with acute episode of LBP Definition: Acute episode Back pain lasting
SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals
Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
C 2 / C 3 N E RVE BLOCKS AND GREATER OCCIPITAL NERVE BLOCK IN CERV I C O G E N I C HEADACHE TREATMENT
C 2 / C 3 N E RVE BLOCKS AND GREATER OCCIPITAL NERVE BLOCK IN CERV I C O G E N I C HEADACHE TREATMENT N u rten Inan, Aysegul Ceyhan, Levent Inan*, Ozlem Kavaklioglu, Alp Alptekin, Nurten Unal Ministry
The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
BOTOX Injection (Onabotulinumtoxin A) for Migraine Headaches [Preauthorization Required]
BOTOX Injection (Onabotulinumtoxin A) for Migraine Headaches [Preauthorization Required] Medical Policy: MP-RX-01-11 Original Effective Date: March 24, 2011 Reviewed: Revised: This policy applies to products
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
Fact Sheet. Queensland Spinal Cord Injuries Service. Pain Management Following Spinal Cord Injury for Health Professionals
Pain Management Following Injury for Health Professionals and Introduction Pain is a common problem following SCI. In the case where a person with SCI does have pain, there are treatments available that
TYPE OF INJURY and CURRENT SABS Paraplegia/ Tetraplegia
Paraplegia/ Tetraplegia (a) paraplegia or quadriplegia; (a) paraplegia or tetraplegia that meets the following criteria i and ii, and either iii or iv: i. ii. iii i. The Insured Person is currently participating
How To Become A Physio And Rehabilitation Medicine Specialist
EUROPEAN BOARD OF PHYSICAL AND REHABILITATION MEDICINE LOGBOOK EUROPEAN UNION OF MEDICAL SPECIALISTS UEMS IDENTIFICATION... 2 INSTRUCTIONS FOR USE... 3 THE TRAINING COURSE... 3 TRAINING PROGRAMME... 4
Differential Diagnosis of Craniofacial Pain
1. Differential Diagnosis of Craniofacial Pain 2. Headache Page - 1 3. International Headache Society International Classification... 4. The Primary Headaches (1-4) Page - 2 5. The Secondary Headaches
Prescription Opioid Addiction and Chronic Pain: Non-Addictive Alternatives To Treatment and Management
Prescription Opioid Addiction and Chronic Pain: Non-Addictive Alternatives To Treatment and Management Dr. Barbara Krantz Medical Director Diplomate American Board of Addiction Medicine 1 Learning Objectives
Pain Management. Practical Applications in Electrotherapy
Pain Management Practical Applications in Electrotherapy The TENS Advantage Deliver Immediate Pain Relief using a unique waveform designed to help prevent nerve accommodation. Manage Dynamic Pain by adjusting
THE COMMONWEALTH OF MASSACHUSETTS Department of Industrial Accidents
THE COMMONWEALTH OF MASSACHUSETTS Department of Industrial Accidents 1 Congress Street, Suite 100 Boston, Massachusetts 02114-2017 DEVAL L. PATRICK Governor PHILIP L. HILLMAN Director TIMOTHY P. MURRAY
AUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
What is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter
What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted
What is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
Frequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice
DISEASE STATE REVIEW Course of Frequent/Daily Headache in the General Population and in Medical Practice Egilius L.H. Spierings, MD, PhD, Willem K.P. Mutsaerts, MSc Department of Neurology, Brigham and
Multiple sclerosis and pain
9 Multiple sclerosis and pain 2ND EDITION Multiple Sclerosis Society of New Zealand CONTENTS Introduction-------------------------------------------------------------------------------------------3 How
Post Acute and Long Term Care: instrument for evaluating outcomes
Post Acute and Long Term Care: instrument for evaluating outcomes National Network for Integrated Continuous Care Portugal RNCCI National Coordination Mission Unit for Integrated Continuous Care J.M. de
AUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
Tension-type headache Non-pharmacological and pharmacological treatment
Danish Headache Center Tension-type headache Non-pharmacological and pharmacological treatment Lars Bendtsen Associate professor, MD, PhD, Dr Med Sci Danish Headache Center, Department of Neurology Glostrup
Whiplash and Cervical Spine Disorders: Evaluation and Management
Whiplash and Cervical Spine Disorders: Evaluation and Management Dr. Corrie Graboski Definition by Quebec Task Force Pain Generators an acceleration-deceleration mechanism of energy transfer to the neck
Guidance on competencies for management of Cancer Pain in adults
Guidance on competencies for management of Cancer Pain in adults Endorsed by: Contents Introduction A: Core competencies for practitioners in Pain Medicine B: Competencies for practitioners in Pain Medicine
Committee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
UBC Pain Medicine Residency Program: CanMEDS Goals and Objectives of the Neurology Rotation
UBC Pain Medicine Residency Program: CanMEDS Goals and Objectives of the Neurology Rotation Goals of the Program To acquire the knowledge and skills necessary to assess and provide a management plan for
Multiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
Interferons (Avonex, Betaferon, Rebif ) for relapsing remitting multiple sclerosis (RRMS)
Interferons (Avonex, Betaferon, Rebif ) for relapsing remitting multiple sclerosis (RRMS) Review Question: What happens when people with RRMS take interferons? The short answer: This review found that
Managing Chronic Pain
Managing Chronic Pain Chronic pain can cripple the body, mind and spirit. Feeling broken? You may benefit from Cleveland Clinic s Section of Pain Medicine, which tailors comprehensive, innovative treatment
Progress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
Drug treatments for neuropathic pain
Understanding NICE guidance Information for people who use NHS services Drug treatments for neuropathic pain NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases
Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
NHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
Extended Abstract. Evaluation of satisfaction with treatment for chronic pain in Canada. Marguerite L. Sagna, Ph.D. and Donald Schopflocher, Ph.D.
Extended Abstract Evaluation of satisfaction with treatment for chronic pain in Canada Marguerite L. Sagna, Ph.D. and Donald Schopflocher, Ph.D. University of Alberta Introduction For millions of people
Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )
Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity
